Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169626 | 0.92 | CXCR4 (0.34) | HTR3A | |
| SCHEMBL24380 | 0.71 | — | — | |
| SCHEMBL4593 | 0.70 | — | — | |
| Ammonia Solution, Strong SCHEMBL28779669 | 0.69 | — | — | |
| Piperazine SCHEMBL28114722 | 0.69 | HIF1A (0.35) | HTR3ASIGMAR1HTR3EHTR3BADRB1 | |
| Hydrochloric Acid SCHEMBL7468053 | 0.69 | ALDH1A1 (0.32) | HTR3ASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL17085839 | 0.67 | HIF1A (0.33) | HTR3ASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL248198 | 0.67 | — | — | |
| SCHEMBL4555498 | 0.67 | — | — | |
| SCHEMBL1582806 | 0.67 | GNAI3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | claimed |
| US-20130274303-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION | YALE UNIVERSITY (US) | 2013-10-17 | — | — | US | disclosed |
| US-20100105748-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2010-04-29 | — | — | US | disclosed |
| WO-2008115706-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION | EMORY UNIVERSITY (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1337523-A2 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6559163-B2 | Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression | NEUROGEN CORPORATION | 2003-05-06 | — | — | US | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002014269-A2 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6008228-A | COMPRISING A MIXTURE OF CARRIER MONOGLYCERIDES OF MEDIUM CHAIN-FATTY ACIDS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0831826-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HTR3A 1651/4885SIGMAR1 4151/4885HTR3E 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.